Why Eiger BioPharmaceuticals Stock Is Jumping Today

  • Eiger BioPharmaceuticals Inc EIGR announced data from the Phase 3 TOGETHER study evaluating Peginterferon Lambda in non-hospitalized COVID-19 adult patients at high risk of progressing to severe illness.
  • Peginterferon Lambda significantly reduced the risk of COVID-19-related hospitalizations or emergency room visits by 50% (primary endpoint) and death by 60%.
  • The Phase 3 TOGETHER study of Lambda is the second largest study to date of a COVID-19 therapeutic. 
  • Final analyses evaluated data from 1,936 patients, with 84% of patients receiving at least a single dose of any COVID-19 vaccine.
  • 2.7% of patients (25 / 916) who received Lambda were hospitalized or had ER visits through Day 28, compared to 5.6% of patients who received placebo
  • 42% risk reduction of COVID-19-related hospitalizations was observed when treated ≤7 days of symptom onset, and 60% when treated ≤3 days.
  • One COVID-19-related death was reported in the Lambda group, and four in the placebo group.
  • Eiger plans to discuss the results with FDA and submit a EUA as soon as possible.
  • The Company licensed worldwide rights to Lambda from Bristol-Myers Squibb Co BMY.
  • Price Action: EIGR shares are up 22.40% at $6.97 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPhase 3 Trialwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!